CVRX vs. NPCE, TELA, SMTI, XAIR, PAVM, SRDX, FNA, SIBN, BVS, and IRMD
Should you be buying CVRx stock or one of its competitors? The main competitors of CVRx include NeuroPace (NPCE), TELA Bio (TELA), Sanara MedTech (SMTI), Beyond Air (XAIR), PAVmed (PAVM), Surmodics (SRDX), Paragon 28 (FNA), SI-BONE (SIBN), Bioventus (BVS), and Iradimed (IRMD). These companies are all part of the "medical" sector.
NeuroPace (NASDAQ:NPCE) and CVRx (NASDAQ:CVRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.
NeuroPace received 8 more outperform votes than CVRx when rated by MarketBeat users. However, 57.14% of users gave CVRx an outperform vote while only 55.81% of users gave NeuroPace an outperform vote.
78.8% of NeuroPace shares are owned by institutional investors. Comparatively, 75.3% of CVRx shares are owned by institutional investors. 22.2% of NeuroPace shares are owned by company insiders. Comparatively, 18.9% of CVRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
NeuroPace has a net margin of -45.61% compared to NeuroPace's net margin of -123.58%. NeuroPace's return on equity of -66.05% beat CVRx's return on equity.
NeuroPace currently has a consensus price target of $15.67, indicating a potential upside of 139.19%. CVRx has a consensus price target of $16.60, indicating a potential upside of 76.22%. Given CVRx's stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroPace is more favorable than CVRx.
In the previous week, NeuroPace had 2 more articles in the media than CVRx. MarketBeat recorded 3 mentions for NeuroPace and 1 mentions for CVRx. CVRx's average media sentiment score of 0.34 beat NeuroPace's score of 0.00 indicating that NeuroPace is being referred to more favorably in the media.
NeuroPace has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, CVRx has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.
NeuroPace has higher revenue and earnings than CVRx. NeuroPace is trading at a lower price-to-earnings ratio than CVRx, indicating that it is currently the more affordable of the two stocks.
Summary
NeuroPace beats CVRx on 14 of the 18 factors compared between the two stocks.
Get CVRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for CVRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CVRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
